Cabozantinib + Placebo
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Differentiated Thyroid Cancer
Conditions
Differentiated Thyroid Cancer
Trial Timeline
Oct 5, 2018 → Jul 31, 2026
NCT ID
NCT03690388About Cabozantinib + Placebo
Cabozantinib + Placebo is a phase 3 stage product being developed by Ipsen for Differentiated Thyroid Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT03690388. Target conditions include Differentiated Thyroid Cancer.
What happened to similar drugs?
1 of 7 similar drugs in Differentiated Thyroid Cancer were approved
Approved (1) Terminated (1) Active (5)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03690388 | Phase 3 | Active |
Competing Products
20 competing products in Differentiated Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CAB-AXL-ADC + PD-1 inhibitor | BioAtla | Phase 1/2 | 22 |
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 44 |
| Lenvatinib + Placebo | Eisai | Phase 3 | 40 |
| Lenvatinib | Eisai | Pre-clinical | 26 |
| Lenvatinib | Eisai | Phase 2 | 27 |
| LENVATINIB | Eisai | Phase 2 | 39 |
| Selpercatinib Monotherapy | Eli Lilly | Phase 2 | 42 |
| Selumetinib + Placebo + Radioactive Iodine Therapy | AstraZeneca | Phase 3 | 32 |
| Pembrolizumab + Cisplatin + Docetaxel + Carboplatin | Merck | Phase 2 | 42 |
| Pembrolizumab | Merck | Phase 2 | 42 |
| sunitinib + everolimus + chemotherapies recommended in france | Novartis | Pre-clinical | 26 |
| Everolimus + Sorafenib | Novartis | Phase 2 | 31 |
| Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo | Novartis | Phase 3 | 44 |
| PDR001 | Novartis | Phase 2 | 35 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 35 |
| Sacituzumab govitecan | Gilead Sciences | Phase 2 | 42 |
| sunitinib | Pfizer | Approved | 43 |
| Vandetanib (SAR390530) + Placebo | Sanofi | Phase 3 | 40 |
| Thyrogen (thyrotropin alfa for injection) | Sanofi | Phase 3 | 40 |
| Cabazitaxel | Sanofi | Phase 2 | 35 |